#Mining and #Biotech #Stocks Added to
Investorideas.com
Mining Companies
Include: TSX: $WG.TO;
TSXV: $AZR.V,
$CAP.V, $CVA.V, $ZFR.V,
$ERA.V; OTC: $ECORF; CSE: $NSM
Point Roberts, WA, Delta BC – August 19, 2016 –
Investorideas.com, a global news source and investor resource covering actively
traded sectors announces this week’s additions to its global stock
directories. Additions within the mining
sector were TSX Listed Companies.
Biotech additions include a cancer treatment
company, an eye treatment company and a company that directs its research
towards treatments for today’s ageing population.
Investorideas.com global stock directories are part
of the membership program on the site, accessed either by login and password or
available in PDF format. The directories
include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized
global stock exchanges, giving retail investors a wide variety of stocks to
review. http://www.investorideas.com/membership/
The directories are not meant as recommendations
but as a research tool to discover opportunities and trading ideas in a
particular sector.
Read this release in full at http://www.investorideas.com/news/2016/main/08191stocks.asp
Mining Companies Added:
Wellgreen Platinum Ltd. (TSX:WG.TO), Azarga Metals Corp (TSX:AZR.V), Castle Peak Mining Ltd.
(TSX:CAP.V), Cava Resources Inc. (TSX:CVA.V), Zephyr Minerals Ltd. (TSX:ZFR.V), ELCORA ADVANCED MATERIALS CORP.
(TSX:ERA.V; OTCQB: ECORF) and Northern Sphere
Mining Corp. (CSE: NSM)
Biotech Companies Added:
Kura Oncology Inc. (NasdaqGS:KURA) is a clinical-stage biopharmaceutical company committed to
realizing the promise of precision medicines for the treatment of cancer. The
company’s pipeline consists of small molecules that target cancer signaling
pathways where there is a strong scientific and clinical rationale to improve
outcomes by identifying those patients most likely to benefit from treatment.
Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase
inhibitor, which is being studied in multiple Phase 2 clinical trials. The
preclinical pipeline includes KO-947, an ERK inhibitor, as well as an inhibitor
of the menin-MLL interaction.
Nymox
Pharmaceutical Corp. (NasdaqCM:NYMX) specializes
in the research and development of novel drugs and diagnostic products for the
aging population. Nymox's lead drug candidate is NX-1207, a proprietary
treatment for enlarged prostate or benign prostatic hyperplasia (BPH). NX-1207
is currently in Phase 3 trials in the United States. Nymox has other new drug
products in development in the fields of cancer, infectious disease,
neurodegenerative diseases, and other areas.
Ocular
Therapeutix Inc. (NasdaqGM:OCUL) is a biopharmaceutical company focused on the development
and commercialization of innovative therapies for diseases and conditions of
the eye using its proprietary hydrogel platform technology. Ocular
Therapeutix's lead product candidate, DEXTENZA™ (dexamethasone insert), is in
Phase 3 clinical development for post-surgical ocular inflammation and pain and
allergic conjunctivitis, and in Phase 2 clinical development for dry eye
disease. A third Phase 3 clinical trial is being conducted for post-surgical
ocular inflammation and pain. For glaucoma and ocular hypertension, the Company
plans to initiate the first of two OTX-TP (sustained release travoprost) Phase
3 clinical trials in the third quarter of 2016. Ocular Therapeutix is also
evaluating sustained-release injectable drug depots for back-of-the-eye
diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved
to seal corneal incisions following cataract surgery.
About Investorideas.com - News that Inspires Big Ideas
Sectors we cover in include mining, energy,
renewable energy, water stocks, food and beverage (including organic and LOHAS,
wine), defense and security, biotech, technology and mobile. We have also expanded
our global coverage to include Latin American stocks, the Middle East, sports
and entertainment.
Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks,
renewable energy, nanotech, defense, technology, biotech and more – use our
stock directories and access them online 24/7 with login as a member to find
your next big idea!
Disclaimer/Disclosure:
Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global
Investors: Effective September 15 2008 - all BC investors should review all OTC
and Pink sheet listed companies for adherence in new disclosure filings and
filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to
regulations of each country.
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment